157 related articles for article (PubMed ID: 29722046)
1. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
[TBL] [Abstract][Full Text] [Related]
2. Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.
Hikino K; Fukunaga K; Mushiroda T
Drug Metab Pharmacokinet; 2018 Dec; 33(6):243-249. PubMed ID: 30360950
[TBL] [Abstract][Full Text] [Related]
3. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic biomarkers in drug labels: what do they tell us?
Tutton R
Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
Imatoh T; Sai K; Saito Y
J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
[TBL] [Abstract][Full Text] [Related]
6. Variability of Pharmacogenomics Information in Drug Labels Approved by Different Agencies and its Ethical Implications.
Güner MD; Ekmekci PE; Kurtoglu B
Curr Drug Saf; 2022; 17(1):47-53. PubMed ID: 34315387
[TBL] [Abstract][Full Text] [Related]
7. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.
Otsubo Y; Asahina Y; Noguchi A; Sato Y; Ando Y; Uyama Y
Drug Metab Pharmacokinet; 2012; 27(1):142-9. PubMed ID: 22201121
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020).
Kim JA; Ceccarelli R; Lu CY
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33806453
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels.
Yoon DY; Lee S; Ban MS; Jang IJ; Lee S
Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
[TBL] [Abstract][Full Text] [Related]
11. Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
Surh LC; Pacanowski MA; Haga SB; Hobbs S; Lesko LJ; Gottlieb S; Papaluca-Amati M; Patterson SD; Hughes AR; Kim MJ; Close SL; Mosteller M; Zineh I; Dechairo B; Cohen NA
Pharmacogenomics; 2010 Dec; 11(12):1637-47. PubMed ID: 21142906
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic information in Swiss drug labels - a systematic analysis.
Jeiziner C; Suter K; Wernli U; Barbarino JM; Gong L; Whirl-Carrillo M; Klein TE; Szucs TD; Hersberger KE; Meyer Zu Schwabedissen HE
Pharmacogenomics J; 2021 Aug; 21(4):423-434. PubMed ID: 33070160
[TBL] [Abstract][Full Text] [Related]
13. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
[TBL] [Abstract][Full Text] [Related]
15. Results of a nationwide survey of Japanese pharmacists regarding the application of pharmacogenomic testing in precision medicine.
Tsuji D; Saito Y; Mushiroda T; Miura M; Hira D; Terada T
J Clin Pharm Ther; 2021 Jun; 46(3):649-657. PubMed ID: 33555613
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic biomarker information on drug labels of the Spanish Agency of Medicines and Sanitary products: evaluation and comparison with other regulatory agencies.
Estévez-Paredes M; Mata-Martín MC; de Andrés F; LLerena A
Pharmacogenomics J; 2024 Jan; 24(1):2. PubMed ID: 38233388
[TBL] [Abstract][Full Text] [Related]
17. Applications of pharmacogenomics in regulatory science: a product life cycle review.
Tan-Koi WC; Leow PC; Teo YY
Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
[TBL] [Abstract][Full Text] [Related]
18. ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels.
Deb S; Hopefl R; Reeves AA; Cvetkovic D
Medicines (Basel); 2024 Feb; 11(3):. PubMed ID: 38535119
[TBL] [Abstract][Full Text] [Related]
19. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
Pritchard D; Patel JN; Stephens LE; McLeod HL
Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
